

Members Obtain Free CE Credits from JCP Articles!



Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol

May 2026 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Learners complete this course will be able to discuss the impact of the drug-drug interaction between lotiglipron and the following agents midazolam, omeprazole, dabigatran, rosuvastatin and the oral contraceptives levonorgestrel and ethinyl estradiol that along with the product's development. This activity is designed to increase knowledge of this new agent and its termination of development.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-26-007-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in the drug–drug interaction potential of lotiglipron.

Learning Objectives

After completing this activity, the learner will be able to:

1. Discuss the metabolic inhibition profile of lotiglipron and its impact upon specific CYP enzymes and drug transporters;
2. Compare and contrast of lotiglipron upon the pharmacokinetics of midazolam, omeprazole, and oral contraceptive levonorgestrel and ethinyl estradiol;
3. Compare and contrast of lotiglipron upon the pharmacokinetics of dabigatran and rosuvastatin;
4. Describe the product's development status from the findings of these drug-drug interaction studies and the phase 2 clinical trial.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE

Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

- Article Selection: John N. van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.
- Planner: Michael W. Jann, PharmD, Retired, planned the continuing education documentation for this course and has nothing to disclose.
- CE Reviewer: Mathangi Gopalakrishnan, MPharm, PhD, Associate Professor, Univ of Maryland School of Pharmacy, served as the CE Reviewer and has nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 5/1/2026

Expiration Date: 5/1/2029

Online Location:

https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14